[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-8l62XtF0bUouav7-apRsU6eVek5YUL3YASOFJRBDCU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"Friends Research Institute, Inc.",[4],43,false,9,10,12121,6,27,[14,16,19,22,25,28,30,32],{"name":15,"count":8},"Opioid Use Disorder",{"name":17,"count":18},"HIV",7,{"name":20,"count":21},"Opioid-use Disorder",5,{"name":23,"count":24},"Methamphetamine Abuse",3,{"name":26,"count":27},"Heroin Addiction",2,{"name":29,"count":27},"Opioid Use",{"name":31,"count":27},"Cocaine Use Disorder",{"name":33,"count":27},"Opiate Dependence",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05944952","Low-dose Versus a High-dose Sublingual Buprenorphine Induction","2024-12-31","buprenorphine\u002Fnaloxone",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04408313","Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail","2026-05-30","XR-B",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07524738","Telemedicine XR-B for Individuals in Jail","2026-07-01","Extended Release Buprenorphine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05766631","Treating Polysubstance Use Using a Novel Digital Technology","2027-06-30","Methadone Treatment-As-Usual",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06306443","Buprenorphine for Individuals in Jail","2029-01-01","extended-release buprenorphine",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,104,137,158,179,200,218,254,272,300,318,336,354,379,397,433,459,484],{"intervention":39,"totalTrials":27,"cells":69},{"EARLY_PHASE1":70,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":91,"NA":102},{"trials":71,"activeCount":72},[],0,{"trials":74,"activeCount":72},[],{"trials":76,"activeCount":72},[],{"trials":78,"activeCount":72},[79],{"nctId":80,"briefTitle":81,"status":82,"phases":83,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":89},"NCT03616236","Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","SUSPENDED",[64],"2026-08-31","2026-12-30","2022-07-01",320,[29],[90],"Buprenorphine\u002FNaloxone",{"trials":92,"activeCount":101,"soonestReadout":38},[93],{"nctId":36,"briefTitle":37,"status":94,"phases":95,"primaryCompletion":38,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":100},"ACTIVE_NOT_RECRUITING",[65],"2025-10-30","2024-06-20",40,[15],[39],1,{"trials":103,"activeCount":72},[],{"intervention":105,"totalTrials":27,"cells":106},"XR-NTX",{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":133,"NA":135},{"trials":108,"activeCount":72},[],{"trials":110,"activeCount":72},[],{"trials":112,"activeCount":72},[],{"trials":114,"activeCount":101,"soonestReadout":43},[115,127],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT02867124","Long-acting Naltrexone for Pre-release Prisoners","COMPLETED",[64],"2025-02-10","2026-01-01","2017-01-01",240,[125],"Opiate Addiction",[105],{"nctId":41,"briefTitle":42,"status":94,"phases":128,"primaryCompletion":43,"completion":129,"start":130,"enrollment":123,"conditions":131,"interventions":132},[63,64],"2026-05-31","2020-10-28",[20],[44,105],{"trials":134,"activeCount":72},[],{"trials":136,"activeCount":72},[],{"intervention":54,"totalTrials":101,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":154,"NA":156},{"trials":140,"activeCount":72},[],{"trials":142,"activeCount":72},[],{"trials":144,"activeCount":72},[],{"trials":146,"activeCount":101,"soonestReadout":53},[147],{"nctId":51,"briefTitle":52,"status":94,"phases":148,"primaryCompletion":53,"completion":149,"start":150,"enrollment":123,"conditions":151,"interventions":153},[64],"2027-09-29","2023-07-26",[29,15,152,31],"Cocaine Use",[54],{"trials":155,"activeCount":72},[],{"trials":157,"activeCount":72},[],{"intervention":49,"totalTrials":101,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":175,"NA":177},{"trials":161,"activeCount":72},[],{"trials":163,"activeCount":72},[],{"trials":165,"activeCount":72},[],{"trials":167,"activeCount":101,"soonestReadout":48},[168],{"nctId":46,"briefTitle":47,"status":94,"phases":169,"primaryCompletion":48,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":174},[64],"2026-09-01","2025-06-01",30,[15],[49],{"trials":176,"activeCount":72},[],{"trials":178,"activeCount":72},[],{"intervention":59,"totalTrials":101,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":196,"NA":198},{"trials":182,"activeCount":72},[],{"trials":184,"activeCount":72},[],{"trials":186,"activeCount":72},[],{"trials":188,"activeCount":101,"soonestReadout":58},[189],{"nctId":56,"briefTitle":57,"status":190,"phases":191,"primaryCompletion":58,"completion":192,"start":193,"enrollment":123,"conditions":194,"interventions":195},"RECRUITING",[64],"2029-04-30","2025-07-01",[15],[59],{"trials":197,"activeCount":72},[],{"trials":199,"activeCount":72},[],{"intervention":44,"totalTrials":101,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":214,"NA":216},{"trials":203,"activeCount":72},[],{"trials":205,"activeCount":72},[],{"trials":207,"activeCount":72},[],{"trials":209,"activeCount":101,"soonestReadout":43},[210],{"nctId":41,"briefTitle":42,"status":94,"phases":211,"primaryCompletion":43,"completion":129,"start":130,"enrollment":123,"conditions":212,"interventions":213},[63,64],[20],[44,105],{"trials":215,"activeCount":72},[],{"trials":217,"activeCount":72},[],{"intervention":219,"totalTrials":27,"cells":220},"Buprenorphine",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":238,"NA":252},{"trials":222,"activeCount":72},[],{"trials":224,"activeCount":72},[],{"trials":226,"activeCount":72},[],{"trials":228,"activeCount":72},[229],{"nctId":230,"briefTitle":231,"status":118,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":237},"NCT04991974","Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine",[63,64],"2026-01-31","2021-09-17",373,[20],[219],{"trials":239,"activeCount":72},[240],{"nctId":241,"briefTitle":242,"status":118,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT01843023","Extended Release Naltrexone for Opioid-Dependent Youth",[65],"2018-01-31","2019-07","2013-06",288,[249],"Drug Dependence",[251,219],"Extended Release Naltrexone",{"trials":253,"activeCount":72},[],{"intervention":251,"totalTrials":101,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":270},{"trials":257,"activeCount":72},[],{"trials":259,"activeCount":72},[],{"trials":261,"activeCount":72},[],{"trials":263,"activeCount":72},[],{"trials":265,"activeCount":72},[266],{"nctId":241,"briefTitle":242,"status":118,"phases":267,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":268,"interventions":269},[65],[249],[251,219],{"trials":271,"activeCount":72},[],{"intervention":273,"totalTrials":101,"cells":274},"Buprenorphine +OTP",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":296,"NA":298},{"trials":276,"activeCount":72},[],{"trials":278,"activeCount":72},[],{"trials":280,"activeCount":72},[],{"trials":282,"activeCount":72},[283],{"nctId":284,"briefTitle":285,"status":118,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT00574067","Buprenorphine for Prisoners",[64],"2013-03","2013-11","2008-09",213,[26],[273,293,294,295],"Buprenorphine +CHC","Counseling +OTP","Counseling +CHC",{"trials":297,"activeCount":72},[],{"trials":299,"activeCount":72},[],{"intervention":293,"totalTrials":101,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":314,"NA":316},{"trials":303,"activeCount":72},[],{"trials":305,"activeCount":72},[],{"trials":307,"activeCount":72},[],{"trials":309,"activeCount":72},[310],{"nctId":284,"briefTitle":285,"status":118,"phases":311,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":312,"interventions":313},[64],[26],[273,293,294,295],{"trials":315,"activeCount":72},[],{"trials":317,"activeCount":72},[],{"intervention":294,"totalTrials":101,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":332,"NA":334},{"trials":321,"activeCount":72},[],{"trials":323,"activeCount":72},[],{"trials":325,"activeCount":72},[],{"trials":327,"activeCount":72},[328],{"nctId":284,"briefTitle":285,"status":118,"phases":329,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":330,"interventions":331},[64],[26],[273,293,294,295],{"trials":333,"activeCount":72},[],{"trials":335,"activeCount":72},[],{"intervention":295,"totalTrials":101,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":350,"NA":352},{"trials":339,"activeCount":72},[],{"trials":341,"activeCount":72},[],{"trials":343,"activeCount":72},[],{"trials":345,"activeCount":72},[346],{"nctId":284,"briefTitle":285,"status":118,"phases":347,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":348,"interventions":349},[64],[26],[273,293,294,295],{"trials":351,"activeCount":72},[],{"trials":353,"activeCount":72},[],{"intervention":355,"totalTrials":101,"cells":356},"Counseling + Transfer",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":375,"NA":377},{"trials":358,"activeCount":72},[],{"trials":360,"activeCount":72},[],{"trials":362,"activeCount":72},[],{"trials":364,"activeCount":72},[365],{"nctId":366,"briefTitle":367,"status":118,"phases":368,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT00378079","Methadone Maintenance for Prisoners",[64],"2008-01","2003-09",211,[26],[355,374],"Counseling + Methadone",{"trials":376,"activeCount":72},[],{"trials":378,"activeCount":72},[],{"intervention":374,"totalTrials":101,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":393,"NA":395},{"trials":382,"activeCount":72},[],{"trials":384,"activeCount":72},[],{"trials":386,"activeCount":72},[],{"trials":388,"activeCount":72},[389],{"nctId":366,"briefTitle":367,"status":118,"phases":390,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":391,"interventions":392},[64],[26],[355,374],{"trials":394,"activeCount":72},[],{"trials":396,"activeCount":72},[],{"intervention":398,"totalTrials":27,"cells":399},"Truvada",{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":401,"activeCount":72},[],{"trials":403,"activeCount":72},[],{"trials":405,"activeCount":72},[406,416],{"nctId":407,"briefTitle":408,"status":118,"phases":409,"primaryCompletion":287,"completion":287,"start":410,"enrollment":411,"conditions":412,"interventions":415},"NCT01140880","Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men",[63],"2010-05",170,[413,414],"HIV Seroconversion","Stimulant Abuse",[398],{"nctId":417,"briefTitle":418,"status":118,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":426},"NCT00856323","Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men",[63],"2010-12","2009-01",53,[424,17,425],"Amphetamine-Related Disorders","HIV Infections",[398],{"trials":428,"activeCount":72},[],{"trials":430,"activeCount":72},[],{"trials":432,"activeCount":72},[],{"intervention":434,"totalTrials":101,"cells":435},"Sublingual tablet 4 mg versus Nicorette Lozenge 4mg",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":437,"activeCount":72},[],{"trials":439,"activeCount":72},[440],{"nctId":441,"briefTitle":442,"status":118,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":450},"NCT02906995","Pharmacokinetics of Nicotine Sublingual Tablets Versus Nicorette Lozenge in Healthy Smokers",[62],"2017-11-27","2017-05-25",24,[448,449],"Tobacco Use Disorder","Cigarette Smoking",[434],{"trials":452,"activeCount":72},[],{"trials":454,"activeCount":72},[],{"trials":456,"activeCount":72},[],{"trials":458,"activeCount":72},[],{"intervention":460,"totalTrials":101,"cells":461},"Pharmacy-based methadone administration and dispensing",{"EARLY_PHASE1":462,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":463,"activeCount":72},[464],{"nctId":465,"briefTitle":466,"status":118,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT04308694","Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment",[61],"2021-01-05","2021-01-18","2020-08-06",20,[20],[460],{"trials":475,"activeCount":72},[],{"trials":477,"activeCount":72},[],{"trials":479,"activeCount":72},[],{"trials":481,"activeCount":72},[],{"trials":483,"activeCount":72},[],{"intervention":485,"totalTrials":101,"cells":486},"Methadone",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":488,"activeCount":72},[],{"trials":490,"activeCount":72},[],{"trials":492,"activeCount":72},[],{"trials":494,"activeCount":72},[],{"trials":496,"activeCount":72},[],{"trials":498,"activeCount":72},[499],{"nctId":500,"briefTitle":501,"status":118,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":508},"NCT02334215","A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail",[66],"2019-03-08","2020-05","2014-12-15",225,[15],[485]]